The Role of Type 1 Angiotensin Receptors on T Lymphocytes in Cardiovascular and Renal Diseases
The renin–angiotensin system plays a critical role in the pathogenesis of several cardiovascular diseases, largely through activation of type I angiotensin (AT1) receptors by angiotensin II. Treatment with AT1 receptor blockers (ARBs) is a proven successful intervention for hypertension and progressive heart and kidney disease. However, the divergent actions of AT1 receptors on individual cell lineages in hypertension may present novel opportunities to optimize the therapeutic benefits of ARBs. For example, T lymphocytes make important contributions to the induction and progression of various cardiovascular diseases, but new experiments indicate that activation of AT1 receptors on T cells paradoxically limits inflammation and target organ damage in hypertension. Future studies should illustrate how these discrepant functions of AT1 receptors in target organs versus mononuclear cells can be exploited for the benefit of patients with recalcitrant hypertension and other cardiovascular diseases.
KeywordsRenin–angiotensin system RAS Angiotensin receptors AT1 receptor blockers ARBs T lymphocyte Adaptive immunity Disease pathogenesis Hypertension Atherosclerosis Myocardial infarction Heart failure Kidney damage Cardiac remodeling
This work was supported by the National Institutes of Health Grant DK087783, the Medical Research Service of the Department of Veterans Affairs, and the Edna and Fred L. Mandel Center for Hypertension and Atherosclerosis Research.
No potential conflicts of interest relevant to this article were reported.
Published papers of particular interest have been highlighted as: • Of importance •• Of major importance
- 21.Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342:821-8.Google Scholar
- 30.••Muller DN, Shagdarsuren E, Park JK, et al. Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol. 2002;161:1679–93. This exhaustive study incorporated multiple immunosuppressive approaches to define a role for T lymphocytes in driving target organ damage during hypertension.PubMedCrossRefGoogle Scholar
- 37.••Marvar PJ, Thabet SR, Guzik TJ, et al. Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension. Circ Res. 2010;107:263–70. This novel set of experiments probes interactions between the central nervous system, the vasculature, and T lymphocytes during the hypertensive response.PubMedCrossRefGoogle Scholar
- 39.•Thabet SR, Wu J, Chen W et al. The Role Of CD8+ T cells, IP-10 And MMP12 In Hypertension. 65th High Blood Pressure Research Conference Conference 2011; Orlando, FL2011. p. 109. These experiments implicate CD8 + cytotoxic T cells in driving blood pressure elevation.Google Scholar
- 40.••Zhang JD, Patel MB, Song YS, et al. A novel role for type 1 Angiotensin receptors on T lymphocytes to limit target organ damage in hypertension. Circ Res. 2012;110:1604–17. This recent study revealed an unusal protective role of the angiotensin receptor on T lymphocytes in hypertension by using conditional gene deletion.PubMedCrossRefGoogle Scholar
- 43.•Barhoumi T, Kasal DA, Li MW, et al. T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension. 2011;57:469–76. This was the first study to suggest that T regulatory cells could blunt the chronic hypertensive response to Ang II.PubMedCrossRefGoogle Scholar
- 45.••Kvakan H, Kleinewietfeld M, Qadri F, et al. Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation. 2009;119:2904–12. In this study, adoptive transfer of T regulatory cells protected against hypertensive cardiac injury through a blood pressure-independent mechanism.PubMedCrossRefGoogle Scholar
- 47.••Zhou X, Nicoletti A, Elhage R, et al. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation. 2000;102:2919–22. These key experiments illustrated how CD4 + T cells potentiate the development of atherosclerosis.PubMedCrossRefGoogle Scholar
- 68.Ince H, Petzsch M, Kleine HD, et al. Prevention of left ventricular remodeling with granulocyte colony-stimulating factor after acute myocardial infarction: final 1-year results of the Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Granulocyte Colony-Stimulating Factor (FIRSTLINE-AMI) Trial. Circulation. 2005;112:I73–80.PubMedCrossRefGoogle Scholar
- 73.•Hofmann U, Beyersdorf N, Weirather J, et al. Activation of CD4+ T lymphocytes improves wound healing and survival after experimental myocardial infarction in mice. Circulation. 2012;125:1652–63. These comprehensive experiments demonstrated that activated CD4 + T lymphocytes improve the outcome of myocardial infarction.PubMedCrossRefGoogle Scholar
- 82.•Kato H, Ishida J, Nagano K, et al. Deterioration of atherosclerosis in mice lacking angiotensin II type 1A receptor in bone marrow-derived cells. Lab Investig. 2008;88:731–9. This provocative study indicated that the type 1 angiotensin receptor in bone marrow-derived cells could protect from atherosclerosis.PubMedCrossRefGoogle Scholar